TD Vaccines A/S

Quick facts

Phase 2 pipeline

• ACE393 · Oncology
  ACE393 is a therapeutic vaccine designed to stimulate immune responses against cancer cells by targeting tumor-associated antigens.
• ACE527

Phase 1 pipeline

• ACE527 vaccine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• TD Vaccines A/S portfolio CI brief
• TD Vaccines A/S pipeline updates RSS